Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCAGN01949 in advanced solid tumors
NCT02923349Phase 2Completed
- Sponsor
- Incyte
- Start
- Oct 2016
- Primary completion
- Mar 2019
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of INCAGN01949 in solid tumor (advanced stage), metastatic solid tumors, endometrial adenocarcinoma and 4 more, sponsored by Incyte. Primary endpoint: Number of Participants With Treatment-related Adverse Events. Started Oct 2016; status: completed.
02
Drugs
INCAGN01949
03
Conditions
solid tumor (advanced stage)metastatic solid tumorsendometrial adenocarcinomaovarian cancerrenal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02923349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02923349.